Radient Pharmaceuticals Corporation fka RXPC

[jimtash]

Interesting. Christiansen seems to be busy with mergers these days. He's also loaning money as well.

The Company entered into an agreement with Michael Christiansen on August 13, 2013 to pay him $123,271.82 (the “Amount Due”) relating to a promissory note, compensation and expenses. These liabilities have been recorded in the accompanying financial statements. The Amount Due will be paid as follows: $10,500 on or before August 15, 2013; $10,500 on or before September 15, 2013; $10,500 on or before October 15, 2013; and the balance in installments of $15,000 beginning on the earlier of (a) the first day of the month following the date on which the company receive at least three million dollars ($3,000,000) of equity funding or (b) December 31, 2014. The Company have the right to prepay this amount without any prepayment penalty. In no event, however, shall the balance due be paid later than December 31, 2014. In the event of a change of control of our company, the company are obligated to pay in full the portion of the Amount Due that remains unpaid. Subject to completion of the payments due under the Agreement, the parties agreed to release all claims against each other related to or arising in connection with the matters that gave rise to our agreement to pay the Amount Due.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9468160


Michael Christiansen

Executive Vice President, Corporate Development and Finance

15+ years investment banking experience with WestPark Capital, Prudential Securities, Seidler Amdec Securities and Laffer Associates. Previously served as CFO with Vizional Technologies and PortaCom Wireless.
Significant experience managing public and private equity offerings, mergers and acquisitions, and strategic advisory engagements in consumer, retailing, software and technology industries.
Advised investment banking clients on over $1.2 billion in aggregate closed transactions.

More About Michael Christiansen

Mr. Christiansen joined the Company in July 2013 as Executive Vice President, Corporate Development. His responsibilities include capital markets, investor relations and corporate administration. He previously served as Executive Vice President and Chief Financial Officer with the Company and Bolcán Mining Corporation prior to the October 2012 merger. In addition, Mr. Christiansen currently serves as a director of Radient Pharmaceuticals Corporation.

http://www.jamesonstanford.com/governance/management/